Bafna Pharmaceuticals today said it has received Ghana health regulator's approval to sell Atenolol tablets, used in the treatment of hypertension, in the Ghana market.
The Chennai-based firm has received the nod for Atenolol tablets from Ghana Food and Drug Administration (FDA) in strengths of 50 and 100 mg, Bafna Pharmaceuticals said in a statement.
"We are extremely pleased to receive FDA approval to market Atenolol tablets 50 mg and 100 mg tablets. It offers an important additional treatment option for physicians and hypertension patients," Bafna Pharmaceuticals CMD Mahaveer Chand Bafna said.
With this approval, the company has so far received nine product approvals from Ghana FDA, it added.
Atenolol can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, angina and to treat and reduce the risk of heart complications following heart attack.
The company has earlier received approvals for various products, including metformin tablets BP 500 mg, fluconazole tablets 150 mg and folic acid.
Further, the company today said its net profit for the second quarter ended September 30, 2010 rose by 4.06 per cent to Rs 1.28 crore, compared to Rs 1.23 crore in the same period last fiscal.
The company's revenues rose by 35 per cent to Rs 22.79 crore, compared to Rs 16.88 crore in the same period previous fiscal.
Shares of the company today closed at Rs 48.20 on the Bombay Stock Exchange, up 0.63 per cent from its previous close.
